High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Côte d'Ivoire, 2018 to 2020.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      on behalf The IeDEA West Africa Collaboration
    • Source:
      Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
    • Publication Information:
      Publication: 1995- : New York, NY : Wiley-Liss
      Original Publication: 1966-1984 : Genève : International Union Against Cancer
    • Subject Terms:
      Uterine Cervical Neoplasms*/epidemiology ; Papillomavirus Infections*/complications ; Papillomavirus Infections*/epidemiology ; HIV Infections*/complications ; HIV Infections*/epidemiology ; Human Papillomavirus Viruses* ; Alphapapillomavirus*; Female ; Humans ; Middle Aged ; Cote d'Ivoire/epidemiology ; Human papillomavirus 18 ; Human papillomavirus 16 ; HIV ; Prevalence
    • Abstract:
      As human papillomavirus (HPV) immunisation and HPV-based cervical cancer (CC) screening programmes expand across sub-Saharan Africa, we investigated the potential impact of human immunodeficiency virus (HIV) status on high-risk (HR)-HPV distribution among women with CC in Côte d'Ivoire. From July 2018 to June 2020, paraffin-embedded CC specimens diagnosed in Abidjan, Côte d'Ivoire were systematically collected and tested for HR-HPV DNA. Type-specific HR-HPV prevalence was compared according to HIV status. Of the 170 CC specimens analysed (median age 52 years, interquartile range: [43.0-60.0]), 43 (25.3%) were from women living with HIV (WLHIV) with a median CD4 count of 526 [373-833] cells/mm 3 and 86% were on antiretroviral therapy (ART). The overall HR-HPV prevalence was 89.4% [95% CI: 84.7-94.1]. All were single HR-HPV infections with no differences according to HIV status (P = .8). Among HR-HPV-positive CC specimens, the most prevalent HR-HPV types were HPV16 (57.2%), HPV18 (19.7%), HPV45 (8.6%) and HPV35 (4.6%), with no significant differences according to HIV status. Altogether, infection with HPV16/18 accounted for 71.1% [95% CI: 55.9-86.2] of CC cases in WLHIV vs 78.9% [95% CI: 71.3-86.5] in women without HIV (P = .3). The study confirms the major role of HPV16/18 in CC in Côte d'Ivoire and should support a regional scale-up of HPV16/18 vaccination programmes regardless of HIV status. However, vaccines targeting additional HR-HPV types, including HPV45 and HPV35, could further decrease future CC incidence in Côte d'Ivoire, both for WLHIV and women without HIV.
      (© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
    • References:
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      Am J Obstet Gynecol. 2016 Mar;214(3):354.e1-6. (PMID: 26433170)
      Lancet Oncol. 2010 Nov;11(11):1048-56. (PMID: 20952254)
      Int J Cancer. 2013 Jan 1;132(1):248-50. (PMID: 22684765)
      Int J Cancer. 2020 Mar 15;146(6):1514-1522. (PMID: 31173641)
      Int J Cancer. 2014 Mar 15;134(6):1389-98. (PMID: 23929250)
      BMJ Open. 2017 Aug 4;7(8):e015123. (PMID: 28780541)
      J Infect Dis. 2018 Apr 23;217(10):1590-1600. (PMID: 29425358)
      AIDS. 2018 Mar 27;32(6):795-808. (PMID: 29369827)
      Trop Med Int Health. 2012 Dec;17(12):1432-40. (PMID: 23107344)
      J Pathol. 1999 Sep;189(1):12-9. (PMID: 10451482)
      J Natl Cancer Inst. 1995 Jun 7;87(11):796-802. (PMID: 7791229)
      Saudi Med J. 2022 May;43(5):538. (PMID: 35537734)
      Lancet HIV. 2018 Jan;5(1):e45-e58. (PMID: 29107561)
      Int J Cancer. 2011 Feb 15;128(4):927-35. (PMID: 20473886)
      N Engl J Med. 2003 Feb 6;348(6):518-27. (PMID: 12571259)
      Virology. 2013 Oct;445(1-2):2-10. (PMID: 23683837)
      Diagnostics (Basel). 2021 May 26;11(6):. (PMID: 34073478)
      J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e1-e6. (PMID: 29781877)
      J Clin Microbiol. 2016 Aug;54(8):2031-8. (PMID: 27225411)
      J Natl Cancer Inst. 2003 Jul 16;95(14):1062-71. (PMID: 12865452)
      J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):332-339. (PMID: 27331659)
      Clin Infect Dis. 2017 May 1;64(9):1228-1235. (PMID: 28199532)
      PLoS One. 2021 Sep 28;16(9):e0257324. (PMID: 34582476)
      IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441. (PMID: 23189750)
      Prev Med. 2021 Mar;144:106399. (PMID: 33388322)
    • Grant Information:
      001 International WHO_ World Health Organization; U01 AI069919 United States AI NIAID NIH HHS
    • Contributed Indexing:
      Keywords: Côte d'Ivoire; cervical cancer; high-risk human papillomavirus; human immunodeficiency virus
    • Subject Terms:
      human papillomavirus 45; human papillomavirus 35
    • Publication Date:
      Date Created: 20231109 Date Completed: 20240123 Latest Revision: 20240324
    • Publication Date:
      20240324
    • Accession Number:
      PMC10841473
    • Accession Number:
      10.1002/ijc.34774
    • Accession Number:
      37942579